SCHEMBL6095783

SCHEMBL6095783

c1cncc(C2CCCC2)c1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.96
CHRNB2 P17787 6/20 0.59
CHRNA4 P43681 6/20 0.59
CHRNA7 P36544 5/20 0.59
CYP2A6 P11509 3/20 0.59
MEN1 O00255 2/20 0.59
CYP2D6 P10635 2/20 0.59
CYP2C19 P33261 2/20 0.59
KMT2A Q03164 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
POLB P06746 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
ALDH1A1 P00352 3/20 0.51
CHRNB4 P30926 2/20 0.51
CHRNA3 P32297 2/20 0.51
CHRNA2 Q15822 2/20 0.51
LMNA P02545 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
HTR3E A5X5Y0 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133904 0.98 CYP11B2 (1.00) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL23873927 0.98 CYP11B2 (1.00) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL14029295 0.98 CYP11B2 (1.00) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL30434052 0.96 CYP11B2 (0.88) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL26154135 0.96 CYP11B2 (0.88) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL29848157 0.91
SCHEMBL990213 0.91
Cyanide SCHEMBL28217286 0.90 CYP11B2 (0.79) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Formic Acid SCHEMBL28324256 0.89 CYP11B2 (0.77) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Ammonia Solution, Strong SCHEMBL28985148 0.89 CYP11B2 (0.77) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105646542-A Method using microwave method to synthesize cefpirome sulfate 上海宁瑞生化技术有限公司 2016-06-08 CN claimed
CN-103539736-B Method for synthesis of 2,3-cyclopentenopyridine from glycerin as raw material INST OF INDUSTRY ZHIJIANG COLLEGE OF ZHEJIANG UNIVERSITY OF TECHNOLOGY 2015-05-13 CN claimed
CN-103601738-A Preparation method of cefpirome hydriodate HARBIN PHARMACEUTICAL GROUP CO LTD GENERAL PHARMACEUTICAL FACTORY 2014-02-26 CN claimed
CN-103539736-A Method for synthesis of 2,3-cyclopentenopyridine from glycerin as raw material IND RES INST ZHIJIANG COLLEGE OF ZHEJIANG UNIV TECHNOLOGY 2014-01-29 CN claimed
CN-102744056-A Ti-V loaded aluminum-pillared montmorillonite heterogeneous catalyst and application thereof UNIV ZHEJIANG TECHNOLOGY 2012-10-24 CN claimed
CN-102584856-A Method for preparing cefpirome sulfate KAIFENG YUGANG PHARMACEUTICAL CO LTD 2012-07-18 CN claimed
CN-101284840-B Synthetic method of cefpirome sulfate XIAOMING GUAN 2012-07-04 CN claimed
CN-102391288-A Preparation methods of cefpirome intermediate and cefpirome QILU ANTIBIOTICS PHARMACEUTICAL CO LTD 2012-03-28 CN claimed
CN-101337970-B Method for synthesizing antibiotic cefpirome sulfate SUZHOU WANQING PHARMACEUTICAL CO LTD 2011-02-02 CN claimed
CN-101747349-A Method for synthesizing cefpirome sulfate SHANDONG XINQUAN MEDICINE INTE 2010-06-23 CN claimed
CN-101456870-A Novel process for synthesizing cefpirome sulfate BEIJING HOPE HUGE PHARM SCI CO (CN) 2009-06-17 CN claimed
CN-101337970-A Synthesis method of antibiotic cefpirome sulfate SUZHOU WANQING PHARMACEUTICAL (CN) 2009-01-07 CN claimed
CN-101284840-A Synthetic method of cefpirome sulfate XIAOMING GUAN (CN) 2008-10-15 CN claimed
CN-1907973-A Process for preparing 2,3-cyclopentene pyridine JINAN CHENGHUI SHUANGDA CHEMIC (CN) 2007-02-07 CN claimed
CN-1680329-A Preparation of pyridine derivative ZHEJIANG INDUSTRY UNIV (CN) 2005-10-12 CN claimed
CN-115677569-B Synthesis method of pyridines and substituted benzenes based on reduction coupling reaction of iron-catalyzed aryl halide and alkyl halide 重庆大学 2024-05-28 CN disclosed
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-08-31 US disclosed
US-20040229864-A1 Sulfone derivatives as 5-HT7 receptor ligands MERCK SHARP & DOHME LTD. (GB) 2004-11-18 US disclosed
CN-1024011-C Process for producing cephalosporin compound TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-03-16 CN disclosed
CN-1050023-A The method for preparing cephalosporin derivative BEECHAM GROUP PLC (GB) 1991-03-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229864-A1 Sulfone derivatives as 5-HT7 receptor ligands HTR7, HTR2C, HTR1A CYP11B2 452/4885CHRNB2 165/4885CHRNA4 208/4885
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A CYP11B2 1165/4885CHRNB2 3330/4885CHRNA4 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.